Exagen Inc. to Participate in Upcoming Investor Conferences

Exagen Inc. (Nasdaq: XGN), based in Carlsbad, California, is a leading provider of diagnostic solutions for autoimmune diseases, committed to enhancing the management and treatment of these chronic conditions. The company specializes in autoimmune testing, with its flagship product, AVISE® CTD, which aids clinicians in accurately diagnosing complex disorders such as lupus, rheumatoid arthritis, and Sjögren’s syndrome. Exagen's innovative testing portfolio offers a full suite of AVISE-branded tests, supporting disease diagnosis, prognosis, and monitoring, ultimately aiming to improve patient care and clinical outcomes.

Recently, Exagen announced its participation in several investor conferences. The management team will engage in one-on-one investor meetings at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 11, 2025, set in Snowbird, Utah. Additionally, Exagen's President and CEO John Aballi along with CFO Jeff Black, will participate in a fireside chat on March 5, 2025, during the TD Cowen’s 45th Annual Health Care Conference in Boston, Massachusetts, which will also feature one-on-one meetings with investors.

Moreover, the management will take part virtually in the 5th Annual KeyBanc Capital Markets Healthcare Forum on March 18, 2025, conducting a fireside chat and engaging in further investor discussions. For more information about these events, interested parties can visit the Events section of Exagen's investor page. Through its commitment to research, innovation, and education, Exagen Inc. continues to address the complexities surrounding autoimmune diseases, reinforcing its position as a key player in the healthcare sector.

Exagen Inc. (Nasdaq: XGN) is carving out a unique niche in the autoimmune diagnostics market, providing essential testing solutions that enhance the diagnosis and management of complex autoimmune conditions. As the company prepares to participate in key upcoming investor conferences, including BTIG's MedTech Conference and TD Cowen's Health Care Conference, stakeholders should closely monitor these events as they present vital opportunities for Exagen to showcase its growth strategy and innovations.

Given Exagen's commitment to advancing diagnostics, particularly through its flagship product, AVISE® CTD, the company is well-positioned to attract interest from investors who prioritize growth potential driven by technological advancements. The focus on improving clinical outcomes through earlier and more accurate diagnostics aligns with the growing market demand for specialized medical testing. As autoimmune diseases become more prevalent, driven by factors like increasing environmental stressors and improved awareness, Exagen's offerings are timely and meaningful.

Investors should consider the impact of management's participation in fireside chats and one-on-one meetings as a vehicle for conveying confidence and strategic vision. These interactions typically lead to heightened investor interest and can positively influence stock performance. By engaging directly with analysts and healthcare investors, Exagen’s leadership can articulate their roadmap for expanding test portfolios and improving market footprint.

However, potential investors should remain cautious and evaluate the competitive landscape in autoimmune diagnostics. As advancements continue, competitors may emerge, potentially impacting Exagen's market share. Keeping a close eye on Exagen's execution of its innovation strategy, coupled with the insights gained from these conferences, can provide valuable guidance in making informed investment decisions. Overall, Exagen Inc. offers growth potential driven by its commitment to innovation in the healthcare sector, making it a compelling consideration for investors focused on the future of diagnostics.